What Is Inhaled Insulin and Who Is It For?

[brentie]

[sayhey24]

This is really great to see. Steve Edelman was said to the the architect of the Onduo protocol. Hopefully, afrezza has been incorporated into it.

[thekindaguyiyam]

wow. very very good.  Just doing it before talking about it is powerful and simple.

[joeypotsandpans]

I will be hitting this up on my phone at my visit to my new primary on Friday with the local MNKD rep with me...it's perfect, he's an Endo and T1 so for this young still wet behind the ears physician (she's about a year out of residency) will be a conversation opener as it is very short, sweet and right to the point! Thanks Brentie!

[sayhey24]

Nice! I would also have the press release with Dr. Kendall's quote about afrezza being the standard of care, highlighted in bright pink.

[dreamboatcruise]

Mar 5, 2018 20:04:24 GMT -5 sayhey24 said:

This is really great to see. Steve Edelman was said to the the architect of the Onduo protocol. Hopefully, afrezza has been incorporated into it.

Where has it even been said that Onduo is developing protocols?  I've recently read about Onduo supporting technology in their app to help recommend dosing of insulin, but that is actually just tying in software that was developed by a different company... and by the looks of it, is likely based on current subq insulins.  I think hoping a Sanofi funded company advocates for Afrezza is a bit of a stretch. 

[porkini]

@1:00 minute mark - 16U? I thought the largest cartridge was 12U, no?

[sportsrancho]

Mar 6, 2018 10:41:22 GMT -5 porkini said:

@1:00 minute mark - 16U? I thought the largest cartridge was 12U, no?

It is.

[sayhey24]

Mar 6, 2018 0:15:41 GMT -5 dreamboatcruise said:

Mar 5, 2018 20:04:24 GMT -5 sayhey24 said:

This is really great to see. Steve Edelman was said to the the architect of the Onduo protocol. Hopefully, afrezza has been incorporated into it.

Where has it even been said that Onduo is developing protocols?  I've recently read about Onduo supporting technology in their app to help recommend dosing of insulin, but that is actually just tying in software that was developed by a different company... and by the looks of it, is likely based on current subq insulins.  I think hoping a Sanofi funded company advocates for Afrezza is a bit of a stretch. 

Google brought $250M of in kind technology.  They're have been working with Dr. Steve Edelman's Taking Control of Your Diabetes (TCOYD) conference community to cull input on their product design process.  www.healthline.com/diabetesmine/sanofi-and-verily-form-onduo

Onduo will focus on the type 2 diabetes community, specifically on developing solutions that could help people make better decisions about their day to day health, ranging from improved medication management to improved habits and goals. The integration of multiple interventions, such as data-driven patient support and devices in addition to treatment, can help improve outcomes.

Onduo is taking a multi-stakeholder approach to diabetes management by involving the diabetes community, clinicians, payers and healthcare professionals in the product development process. Additionally, Onduo is discussing with patient advocacy groups like Taking Control of Your Diabetes (TCOYD) to provide input on future product designs.

"With Onduo, Sanofi and Verily are bringing forward a platform that is novel and critical in diabetes management," said Steven V. Edelman, M.D., Founder and Director, TCOYD. "Onduo is a company focused on the improvement of health outcomes through the marriage of technology and medicine.
www.prnewswire.com/news-releases/sanofi-and-verily-life-sciences-announce-launch-of-onduo-a-joint-venture-to-develop-comprehensive-diabetes-management-platform-300326057.html

A lot of the $250M Google brought was predictive modeling assuming a many variable really hard problem.  With afrezza its a lot easier as its more of a flow control problem once you model baseline food interactions.  More over IMO a lot of the complex modeling Onduo was planning to do is just not needed with afrezza.  At this point in time we will just have to see what they come to market with which should be pretty soon. 

[peppy]

Mar 6, 2018 19:35:12 GMT -5 sayhey24 said:

Mar 6, 2018 0:15:41 GMT -5 dreamboatcruise said:

Where has it even been said that Onduo is developing protocols?  I've recently read about Onduo supporting technology in their app to help recommend dosing of insulin, but that is actually just tying in software that was developed by a different company... and by the looks of it, is likely based on current subq insulins.  I think hoping a Sanofi funded company advocates for Afrezza is a bit of a stretch. 

Google brought $250M of in kind technology.  They're have been working with Dr. Steve Edelman's Taking Control of Your Diabetes (TCOYD) conference community to cull input on their product design process.  www.healthline.com/diabetesmine/sanofi-and-verily-form-onduo

Onduo will focus on the type 2 diabetes community, specifically on developing solutions that could help people make better decisions about their day to day health, ranging from improved medication management to improved habits and goals. The integration of multiple interventions, such as data-driven patient support and devices in addition to treatment, can help improve outcomes.

Onduo is taking a multi-stakeholder approach to diabetes management by involving the diabetes community, clinicians, payers and healthcare professionals in the product development process. Additionally, Onduo is discussing with patient advocacy groups like Taking Control of Your Diabetes (TCOYD) to provide input on future product designs.

"With Onduo, Sanofi and Verily are bringing forward a platform that is novel and critical in diabetes management," said Steven V. Edelman, M.D., Founder and Director, TCOYD. "Onduo is a company focused on the improvement of health outcomes through the marriage of technology and medicine.
www.prnewswire.com/news-releases/sanofi-and-verily-life-sciences-announce-launch-of-onduo-a-joint-venture-to-develop-comprehensive-diabetes-management-platform-300326057.html

A lot of the $250M Google brought was predictive modeling assuming a many variable really hard problem.  With afrezza its a lot easier as its more of a flow control problem once you model baseline food interactions.  More over IMO a lot of the complex modeling Onduo was planning to do is just not needed with afrezza.  At this point in time we will just have to see what they come to market with which should be pretty soon. 

When Onduo can come out with a non invasive glucose monitor, then they would be talking. Until then, it is just service.

[sayhey24]

When Google(Onduo)and Apple both come out with their watches it will be awesome for everyone but Kevin Sayer. Until then Onduo is in the deal with Dexcom for the G6 but I am not sure about the M&M (https://verily.com/). The M&M is IMO good enough for all diabetics but the Watch is for the general public and the 100M who have no idea they are diabetic will all of a sudden start looking for the afrezza. Mike better figure out a way to sell it over the counter by then.

[peppy]

Mar 6, 2018 20:21:10 GMT -5 sayhey24 said:

When Google(Onduo)and Apple both come out with their watches it will be awesome for everyone but Kevin Sayer. Until then Onduo is in the deal with Dexcom for the G6 but I am not sure about the M&M (https://verily.com/). The M&M is IMO good enough for all diabetics but the Watch is for the general public and the 100M who have no idea they are diabetic will all of a sudden start looking for the afrezza. Mike better figure out a way to sell it over the counter by then.

that's the ticket, giving site to the blind.

[thekindaguyiyam]

Mar 5, 2018 20:10:13 GMT -5 thekindaguyiyam said:

wow. very very good.  Just doing it before talking about it is powerful and simple.

this could be a commercial.   Matter of fact and to the point within 30 seconds.
I think this is a winner.   brilliant!

[agedhippie]

Mar 6, 2018 20:21:10 GMT -5 sayhey24 said:

When Google(Onduo)and Apple both come out with their watches it will be awesome for everyone but Kevin Sayer. Until then Onduo is in the deal with Dexcom for the G6 but I am not sure about the M&M (https://verily.com/). The M&M is IMO good enough for all diabetics but the Watch is for the general public and the 100M who have no idea they are diabetic will all of a sudden start looking for the afrezza. Mike better figure out a way to sell it over the counter by then.

If they are still in the deal with Dexcom when the M&M sensor is launched then Onduo will have it. I can see Onduo taking on other CGMs as they become available and are available on Medicare, but right now Dexcom is the only CGM approved by Medicare and that's a big part of the Type 2 market, (which is Onduo's target).

I will believe the watch when I see it. People have been trying to get non-invasive technologies working for decades and are still no nearer that I know of.

[sayhey24]

Getting Medicare approval does not seem like a big hurdle. The Libre was approved in September and got Medicare by January.
www.ajmc.com/newsroom/abbotts-freestyle-libre-cgm-gains-medicare-coverage

Since Onduo is a Verily company and Verily currently has a deal in place with Dexcom the only CGM Onduo will use at this point is Dexcoms. However, I am not sure if Dexcom has rights to the M&M. This may be 100% Verily but I am not sure. If Dexcom has no rights once its available Ondou will move to this and Dexcom will be cut out.

Dexcom at this point has no part of the watch. The watch is real and so is Apple's. You won't see it for another 3 years for marketing reasons. However, it is a fitness device not to be used for dosing.